399 related articles for article (PubMed ID: 36719097)
41. Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM.
Long A; Salvo M
Ann Pharmacother; 2022 Sep; 56(9):1041-1048. PubMed ID: 35021925
[TBL] [Abstract][Full Text] [Related]
42. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Li P; Cui Y; Xu X; Dong J; Liao L
Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
[TBL] [Abstract][Full Text] [Related]
43. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
[TBL] [Abstract][Full Text] [Related]
44. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
Chaudhuri A; Ghanim H; Arora P
Diabetes Obes Metab; 2022 Mar; 24(3):365-376. PubMed ID: 34779091
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
46. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
Epstein M
Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
[TBL] [Abstract][Full Text] [Related]
47. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
[TBL] [Abstract][Full Text] [Related]
48. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
49. Finerenone.
Vachek J; Tesař V
Vnitr Lek; 2023; 69(E-3):20-23. PubMed ID: 37468332
[TBL] [Abstract][Full Text] [Related]
50. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Green JB; Mottl AK; Bakris G; Heerspink HJL; Mann JFE; McGill JB; Nangaku M; Rossing P; Scott C; Gay A; Agarwal R
Nephrol Dial Transplant; 2023 Mar; 38(4):894-903. PubMed ID: 35700142
[TBL] [Abstract][Full Text] [Related]
51. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
Shah M; Awad AS; Abdel-Rahman EM
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
[TBL] [Abstract][Full Text] [Related]
52. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
[TBL] [Abstract][Full Text] [Related]
53. Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Koya D; Anker SD; Ruilope LM; Rossing P; Liu Z; Lee BW; Lee CT; Scott C; Kolkhof P; Lawatscheck R; Wang L; Joseph A; Pitt B;
Am J Nephrol; 2023; 54(9-10):370-378. PubMed ID: 37708857
[TBL] [Abstract][Full Text] [Related]
54. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
55. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
[TBL] [Abstract][Full Text] [Related]
56. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
57. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P; Anker SD; Filippatos G; Pitt B; Ruilope LM; Birkenfeld AL; McGill JB; Rosas SE; Joseph A; Gebel M; Roberts L; Scheerer MF; Bakris GL; Agarwal R;
Diabetes Care; 2022 Dec; 45(12):2991-2998. PubMed ID: 35972218
[TBL] [Abstract][Full Text] [Related]
58. [The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist's treatment: A review].
Bobkova IN
Ter Arkh; 2023 Nov; 95(9):796-801. PubMed ID: 38158924
[TBL] [Abstract][Full Text] [Related]
59. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Advances in Diabetic Kidney Disease.
Georgianos PI; Vaios V; Eleftheriadis T; Papachristou E; Liakopoulos V
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]